Han Lian-shu, Ye Jun, Qiu Wen-juan, Zhang Hui-wen, Wang Yu, Ji Wen-jun, Gao Xiao-lan, Li Xiao-yan, Jin Jing, Gu Xue-fan
Department of Pediatric Endocrinologic and Genetic Metabolism, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhonghua Er Ke Za Zhi. 2012 Jun;50(6):405-9.
Many children were found to have low free carnitine level in blood by tandem mass spectrometry technology. In some of the cases the problems occurred secondary to malnutrition, organic acidemia and other fatty acid oxidation metabolic diseases, and some of cases had primary carnitine deficiency (PCD). In the present article, we discuss the diagnosis of PCD and evaluate the efficacy of carnitine in the treatment of PCD.
We measured the free carnitine (C0) and acylcarnitine levels in the blood of 270 000 neonates from newborns screening program and 12 000 children with suspected clinical inherited metabolic diseases by tandem mass spectrometry. The mutations of carnitine transporter protein were tested to the children with low C0 level and the diagnosis was made. The children with PCD were treated with 100 - 300 mg/kg of carnitine.
Seventeen children were diagnosed with PCD, 6 from newborn screening program and 11 from clinical patients. Mutations were found in all of them. The average C0 level [(2.9 ± 2.0) µmol/L] in patients was lower than the reference value (10 µmol/L), along with decreased level of different acylcarnitines. The clinical manifestations were diverse. For the 6 patients from newborn screening, 4 were asymptomatic, 1 showed hypoglycaemia and 1 showed movement intolerance from 2 years of age. For the 11 clinical patients, 8 showed hepatomegaly, 7 showed myasthenia, 6 showed cardiomyopathy, 1 showed chronic abdominal pain, and 1 showed restlessness and learning difficulty. Among these patients, 14 cases were treated with carnitine. Their clinical symptoms disappeared 1 to 3 months later. The C0 level in the blood rose to normal, with the average from (4.0 ± 2.7) µmol/L to (20.6 ± 8.3) µmol/L (P < 0.01). However, the level was still lower than the average level of healthy children [(27.1 ± 4.5) µmol/L, P < 0.01].
Seventeen patients were diagnosed with PCD by the test levels of free carnitine and acylcarnitines in blood with tandem mass spectrometry, and gene mutation test. Large dose of carnitine had a good effect in treatment of the PCD patients.
通过串联质谱技术发现许多儿童血液中游离肉碱水平较低。在某些情况下,这些问题继发于营养不良、有机酸血症和其他脂肪酸氧化代谢疾病,还有一些病例患有原发性肉碱缺乏症(PCD)。在本文中,我们讨论PCD的诊断,并评估肉碱治疗PCD的疗效。
我们通过串联质谱法测量了来自新生儿筛查项目的270000名新生儿以及12000名疑似临床遗传性代谢疾病儿童血液中的游离肉碱(C0)和酰基肉碱水平。对C0水平较低的儿童进行肉碱转运蛋白突变检测并做出诊断。对PCD患儿给予100 - 300mg/kg的肉碱进行治疗。
17名儿童被诊断为PCD,其中6名来自新生儿筛查项目,11名来自临床患者。所有患儿均发现有突变。患者的平均C0水平[(2.9±2.0)μmol/L]低于参考值(10μmol/L),同时不同酰基肉碱水平降低。临床表现多样。在新生儿筛查的6名患者中,4名无症状,1名出现低血糖,1名从2岁起表现为运动不耐受。在11名临床患者中,8名出现肝肿大,7名出现肌无力,6名出现心肌病,1名出现慢性腹痛,1名出现烦躁不安和学习困难。在这些患者中,14例接受了肉碱治疗。1至3个月后他们的临床症状消失。血液中的C0水平升至正常,平均从(4.0±2.7)μmol/L升至(20.6±8.3)μmol/L(P<0.01)。然而,该水平仍低于健康儿童的平均水平[(27.1±4.5)μmol/L,P<0.01]。
通过串联质谱法检测血液中游离肉碱和酰基肉碱水平以及基因突变检测,确诊了17例PCD患者。大剂量肉碱对PCD患者有良好的治疗效果。